Sep 18,2020 02:18 PM
Laurus Labs jumped 5.74% to Rs 1486.20, extending gains for tenth consecutive session.
Laurus Labs Ltd leads losers in A group Aug 11,2020
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Apollo Hospitals Enterprise Ltd||1,828.45||213.39||25,442.51||-149.11||0.33||1,961.52||286.67|
|Dr Lal Pathlabs Ltd||1,986.15||85.17||16,581.46||28.80||0.60||255.00||124.83|
|Laurus Labs Ltd||1,493.50||39.17||16,011.24||158.78||0.17||970.41||169.74|
|Fortis Healthcare Ltd||132.95||0.00||10,059.82||19.90||0.00||100.56||117.58|
|Metropolis Healthcare Ltd||1,868.00||89.49||9,520.40||2.19||0.43||110.78||100.62|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (P... More
Reports by laurus-labs
Sep 20, 2020 11:06 AM
The company’s consolidated revenue stood at Rs529.46cr, up 10.55% yoy but down 10% qoq.
30 Jul 2020
21 Jul 2020
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedul... More
09 Jul 2020
11 Jun 2020
AGM 09/07/2020Pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015, we enclose the Notice conv... More
30 Apr 2020
01 Jul 2020
Outcome of Board Meeting for April 30, 2020... More